When was Atomoxetine (Strattera) launched? When was Atomoxetine (Strattera) launched? Atomoxetine was approved for marke

When was Atomoxetine (Strattera) launched?
When was Atomoxetine (Strattera) launched? Atomoxetine was approved for marketing by the US Food and Drug Administration (FDA) in 2002, and was approved for marketing by the China Drug Administration on August 31, 2023.
Among children and adolescents, attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. This disorder can have a negative impact on an individual's academic performance, social relationships, and quality of life. In order to help these patients better manage and control their symptoms, Atomoxetine (Strattera) has been introduced into clinical practice as a new type of drug. The following will introduce and discuss the launch time of Atomoxetine (Strattera).

1. Atomoxetine (Strattera): A new drug for treating ADHD
   Over the past few decades, the medical community has been searching for drugs that can effectively treat ADHD. Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor (SNRI). As a non-stimulant drug, it can have a positive impact on ADHD symptoms. Different from stimulant drugs (such as methamphetamine), Strattera improves attention and inhibitory control function by increasing the level of the neurotransmitter norepinephrine in the brain.

2. The launch time of Atomoxetine (Strattera)
   Atomoxetine was developed by the Irish pharmaceutical company Eli Lilly and Company. The company submitted a New Drug Application (NDA) in 2002 and was approved by the US Food and Drug Administration (FDA). According to the approval of the FDA, Atomoxetine (Strattera) was officially launched in the same year, becoming a new choice for treating ADHD in children and adolescents.

3. The clinical application of Atomoxetine (Strattera)
   Atomoxetine (Strattera) has a wide range of applications and is suitable for children, adolescents, and adult patients aged 6 and above. It can alleviate symptoms such as inattention, hyperactivity, and impulsive behavior in ADHD patients. By adjusting the balance of neurotransmitters, Strattera helps improve the academic performance, social skills, and daily functions of patients.

4. The potential benefits and precautions of Atomoxetine (Strattera)
   Compared with other ADHD treatment drugs, the potential benefits of Strattera are that it does not have the risk of addiction and abuse. In addition, it can help ADHD patients deal with adverse reactions caused by psychological stimulants (such as insomnia and appetite suppression, etc.). Patients and doctors should fully understand its side effects and contraindications before using Strattera to ensure safe and effective treatment.
   In summary, Atomoxetine (Strattera) plays an important role in the treatment of ADHD in children and adolescents as a new type of drug. Its characteristics of being non-stimulating and not causing addiction provide patients with an effective and safe treatment option. For patients and doctors using Strattera, it is crucial to understand its side effects and contraindications to ensure rational use and maximize its therapeutic effect.